Home/Pipeline/HELIOGEN®

HELIOGEN®

Ocular Surface Disease

CommercialMarketed

Key Facts

Indication
Ocular Surface Disease
Phase
Commercial
Status
Marketed
Company

About MiMedx Group

MiMedx Group is a vertically integrated biopharmaceutical company focused on developing, processing, and commercializing regenerative placental tissue allografts for advanced wound care and surgical applications. Its core competitive advantage is the proprietary PURION® processing platform, which preserves the biological integrity of the tissue to create a diverse portfolio of products. The company has achieved significant commercial traction with over three million allografts distributed and payer coverage for over 300 million lives, positioning it as a leader in the placental biologics space. MiMedx's strategy centers on expanding its clinical evidence, penetrating existing markets, and exploring new surgical indications to drive growth.

View full company profile